

## Curis Announces Abstract for CI-8993 Accepted for Presentation at the Society for Immunotherapy of Cancer's (SITC) 35th Anniversary Annual Meeting

LEXINGTON, Mass., Oct. 14, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that a Trial in Progress abstract for CI-8993, a first-in-class monoclonal anti-VISTA antibody, has been accepted for poster presentation at the Society for Immunotherapy of Cancer's (SITC) 35<sup>th</sup> Anniversary Annual Meeting, which will be held virtually from November 9-14, 2020.

Details of the poster session are as follows:

**Title:** Phase 1 Study of CI-8993 anti-VISTA antibody in patients with advanced solid tumor malignancies

**Author:** Melissa L. Johnson, MD, *Sarah Cannon Research Institute*

**Date & Time:** Wednesday, November 11<sup>th</sup>, 2020 – Saturday, November 14<sup>th</sup>, 2020 from 9:00 am – 5:00 pm ET

**Abstract ID:** 743

Additional meeting information can be found on the SITC website at [www.sitcancer.org](http://www.sitcancer.org). The poster presentation will also be available under "Events and Presentations" in the Investors section of the Company's website at [www.curis.com](http://www.curis.com)

### About Curis, Inc.

Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. In 2015, Curis entered into a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including, the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor, CA-4948. CA-4948 is currently undergoing testing in a Phase 1 trial in patients with non-Hodgkin lymphoma and in a Phase 1 trial in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, Curis is engaged in a collaboration with ImmuNext for development of CI-8993, a monoclonal anti-VISTA antibody, which is currently undergoing testing in a Phase 1a/1b trial in patients with solid tumors. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge<sup>®</sup> for the treatment of advanced basal cell carcinoma. For more information, visit Curis' website at [www.curis.com](http://www.curis.com).

SOURCE Curis, Inc.

For further information: Investor Relations, Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, [stephanie.ascher@sternir.com](mailto:stephanie.ascher@sternir.com)

---

<https://investors.curis.com/2020-10-14-Curis-Announces-Abstract-for-CI-8993-Accepted-for-Presentation-at-the-Society-for-Immunotherapy-of-Cancers-SITC-35th-Anniversary-Annual-Meeting>